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Abstract
CXCL8/interleukin-8 is a pro-inflammatory chemokine that triggers pleiotropic responses, including inflammation,
angiogenesis, wound healing and tumorigenesis. We engineered the first selective CXCR1 agonists on the basis of residue
substitutions in the conserved ELR triad and CXC motif of CXCL8. Our data reveal that the molecular mechanisms of
activation of CXCR1 and CXCR2 are distinct: the N-loop of CXCL8 is the major determinant for CXCR1 activation, whereas the
N-terminus of CXCL8 (ELR and CXC) is essential for CXCR2 activation. We also found that activation of CXCR1 cross-
desensitized CXCR2 responses in human neutrophils co-expressing both receptors, indicating that these novel CXCR1
agonists represent a new class of anti-inflammatory agents. Further, these selective CXCR1 agonists will aid at elucidating
the functional significance of CXCR1 in vivo under pathophysiological conditions.
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Introduction
The onset of inflammation is mediated by the secretion of
chemokines, which initiate the immigration of leukocytes from
circulation to the site of injury and infection. The canonical
chemokine CXCL8 (IL-8) binds with high affinity to two highly
homologous chemokine receptors CXCR1 and CXCR2, which
mediate pleiotropic responses including the onset of inflammation,
angiogenesis, tumorogenesis and wound healing [1]. Chemokines are
folded into three antiparallel b-sheets and a a helix on the top, with
an unstructured N-terminus containing the ELR triad, and the CXC
motif which connects the ELR to the N-loop and the 30 s loop [2].
The functional significance of CXCR1, the cross-talk between
CXCR1 and CXCR2 in cells co-expressing both receptors, and their
mechanisms of activation by CXCL8 and related ELR-CXC
chemokines, are currently unknown. Whereas the functional role of
CXCR2 can be examined by using CXCR2-deficient mice [3] or the
administrationofCXCR2selectiveagonists(CXCL1-3andCXCL5-
7) or non-peptide CXCR2 antagonists [4], elucidating the role of
CXCR1 in vivo is hampered by the lack of specific CXCR1 agonists
and antagonists, and because mice and rat do not express CXCR1 in
neutrophils and they do not express the human homologue of
CXCL8 [5]. An argument is that CXCR1 is redundant; however the
importance of CXCR1 was highlighted by studies suggesting that
CXCR1 plays a significant role on the regulation and progression of
chronic inflammatory disorders, including cystic fibrosis, COPD, and
in sporadic urinary infections [6,7].
On the basis of numerous mutagenesis and structural studies of
chemokines and their cognate receptors, a two-site model was
postulated for the interactions of chemokines with their cognate
receptors [8]. Site 1 includes the receptor N-terminus, which
recognizes the N-loop of chemokines, and site 2 includes
extracellular loops of the receptor for binding to the N-terminus
of chemokines to trigger receptor activation. This model, however,
fails to account for the selective interaction of CXCR1 with
CXCL8, and the non-selective interactions of CXCR2 with all
ELR-CXC-chemokines, including those chemokines containing
transplanted ELR triads into the nonELR-CXCL4 or the pseudo
ELR in MIF1a [9,10]. In this work, we have engineered CXCL8
derivatives via modifications in its N-terminus (ELR and CXC)
and discovered novel CXCR1 agonists, which have allowed
identifying the major interactions between ELR-CXC chemokines
with their cognate receptors and probing the functional cross-talk
between CXCR1 and CXCR2 in human neutrophils co-
expressing both receptors.
Results
Engineering of CXCR1 Agonists
To identify the sites in CXCL8 responsible for binding to
CXCR e engineered CXCL8 derivatives by residue substitutions
or deletions in the N-terminus of CXCL8 spanning the ELR triad
and CXC motif. We found that CXCL8 mutants with residue
substitutions of Arg6 in the ELR triad failed to increase the
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in Jurkat cells expressing receptors for CXC or CC chemokines
(data not shown). However, most of these CXCL8 mutants
activated CXCR1, as demonstrated by the increase in intracellular
calcium in HL-60 cells expressing CXCR1, according to the
following agonist ranking His.Gly.Lys.Ala (Fig. 1, Fig S1). In
contrast the CXCL8 mutant with Asp substitution in the Glu4 site
of the ELR motif triggered weaker calcium responses than wild-
type CXCL8 in HL-60 cells expressing CXCR1 or CXCR2 (data
not shown), suggesting that Glu4 site is not important for the
selective activation of receptor subtypes.
Dose-response analysis showed that the CXCL8 derivative
(R6H-CXCL8) was a full CXCR1 agonist for calcium responses,
although with a 13-fold higher EC50 than wild-type CXCL8
(Fig. 2A); moreover this mutant displaced the
125I-CXCL8 bound
to CXCR1 but did not displace
125I-CXCL8- or
125I-CXCL1-
bound to HL60 cells expressing CXCR2 (Fig. 2B, Fig S2).
Similarly, the single residue deletion CXCL8 mutant CC-CXCL8
(CC replaced CXC) is also a selective full CXCR1 agonist but with
a 100-fold higher EC50 than wild-type CXCL8 (Fig S3), as we
previously described [11]. Accordingly, both R6H-CXCL8 and
CC-CXCL8 triggered internalization of CXCR1 but not of
CXCR2 (Fig. 3). To demonstrate the inflammatory activity of
R6H-CXCL8 and CC-CXCL8 we used the rabbit model of skin
inflammation, as rabbits like humans express CXCR1 and
CXCR2 in neutrophils. Most importantly, rabbit express the
human homologous of CXCL8, and rabbit CXCR1 and CXCR2
in neutrophils are functionally and pharmacologically similar to
human CXCR1 and CXCR2 in neutrophils [12,13]. Further-
more, R6H-CXCL8 did not displace the
125I-CXCL8 bound to
CHO cells expressing rabbit CXCR2 (data not shown), suggesting
that rabbit and human CXCR2 do not bind with high affinity to
R6H-CXCL8. We found that that subcutaneous administration of
R6H-CXCL8, CC-CXCL8, or CXCL8 in rabbits elicited skin
inflammation (Fig S4), as demonstrated by the accumulation of
neutrophils in the injection sites. These findings are in agreement
with the failure of CC-CXCL8 to recruit neutrophils into mice
lungs, as murine neutrophils do not express CXCR1 [11]. In
contrast to the R6H-CXCL8 mutant, CC-CXCL8 binds with low
affinity to CXCR2 (Fig S2). Interestingly, likewise to CXCR2 the
decoy chemokine receptor DARC, which binds ELR-CXC and
CCL2/CCL5 chemokines [14] failed to bind to R6H-CXCL8 or
CC-CXCL8, as they did not displace the
125I-CXCL1 bound to
DARC in ghost membranes from human red blood cells (Fig S5).
These results showed for the first time the generation of selective
CXCR1 agonists, but most importantly our data reveal that the N-
terminus of CXCL8 contains the major determinants for the
binding and activation of CXCR2 and binding to DARC, but not
for CXCR1.
Functional significance of CXCR1
The CXCR1 agonists identified in assays with HL-60 cells
expressing CXCR1 or CXCR2 were probed in human neutro-
phils, which co-express both receptors. As expected we found that
CXCL8 induced increase of intracellular calcium in neutrophils
treated or untreated with the CXCR2 antagonist SB225002 [4]
(Fig. 4A and 4D), as CXCL8 activates both CXCR1 and
CXCR2. In contrast, the CXCR2 agonist CXCL1 did not induce
calcium responses in neutrophils treated with SB225002 (Fig. 4B
and 4E). Of importance, the CXCR1 agonists R6H-CXCL8
triggered calcium responses in neutrophils untreated or treated
with SB225002 (Fig. 4C and 4F), further validating the selective
activation of CXCR1 by R6H-CXCL8. Similarly, the CXCR1
agonists R6K, R6G and CC-CXCL8 also elicited calcium
responses in neutrophils treated with SB225002, although at
higher concentrations than R6H-CXCL8 or CXCL8 (Fig S6).
To examine the functional interactions between CXCR1 and
CXCR2 we probed the desensitization of calcium responses in
neutrophils mediated by each receptor using the newly identified
CXCR1 agonists (R6H-CXCL8 and CC-CXCL8). Both CXCR1
agonists R6H-CXCL8 and CC-CXCL8 desensitized the calcium
responses mediated by the same agonists, as demonstrated by the
lack of calcium response to a second agonist challenge (Fig. 5A
and 5B). Interestingly, activation of CXCR1 by R6H-CXCL8
did not desensitized the calcium response to the CXCR2 agonist
CXCL1, whereas CC-CXCL8 completely desensitized the
responses to CXCL1 (Fig. 5C and 5D), indicating that these
two CXCR1 agonists trigger distinct desensitization signals. As
controls, CC-CXCL8 did not desensitize the CXCR2-mediated
calcium responses in HL-60 cells expressing only CXCR2 (Fig
S7), ruling out that the CC-CXCL8 desensitizes CXCR2
responses via the binding to CXCR2, as shown in Fig S2.
Furthermore, activation of CXCR2 by CXCL1 did not desensitize
the responses mediated by R6H-CXCL8 or CC-CXCL8 (Fig. 5E
and 5F). Together, these results show that CXCR1 can elicit
signals to desensitize calcium responses mediated by CXCR2 in a
unidirectional fashion, as CXCR2 activation does not desensitize
the CXCR1 responses.
Figure 1. The R6H-CXCL8 mutant triggered calcium responses
in HL-60 cells expressing CXCR1. HL-60 cells expressing CXCR1 or
CXCR2 loaded with Indo-1 were stimulated with 100 nM of CXCL8,
CXCL1 or R6H-CXCL8 mutant. The percentages of intracellular calcium
responses are estimated from the calcium signal elicited by permea-
bilization of the cells with the detergent dodecylmaltoside (referred as
100%). The record is representative of at least five independent
experiments.
doi:10.1371/journal.pone.0027967.g001
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binding selective CXCR1 agonists
We investigated whether the N-terminus of CXCR1 is essential
for binding to R6H-CXCL8 and CC-CXCL8. We constructed a
receptor chimera, in which the N-terminus of CXCR2 was
replaced for the N-terminus of CXCR1. This chimera bound
R6H-CXCL8 and CC-CXCL8 (Fig. 6). Interestingly this chimera
failed to bind CXCL1. These findings are in good agreement with
our previous studies with CXCR1/CXCR2 chimeras [15], in
which the reciprocal exchange of N-termini switched the
chemokine binding selectivity of the chimeric receptors. Moreover,
we previously showed the important role of the CXCR1 N-
terminus for binding to CXCL8 by transplanting the CXCR1 N-
terminus into the mouse CXCR2, resulting in a mouse CXCR2
mutant exhibiting high affinity binding to CXCL8 [16].
Discussion
These novel chemokine derivatives (R6H-CXCL8 and CC-
CXCL8) represent the first generation of CXCR1 agonists, which
will aid in probing the functional significance of CXCR1 in vivo
under pathophysiological conditions, in particular in tissues co-
expressing CXCR1, CXCR2 and DARC. In fact, we found that
activation of human neutrophils, which co-express CXCR1 and
CXCR2, with the newly engineered CXCR1 agonists desensitized
the calcium responses mediated by CXCR2, but activation of
CXCR2 did not desensitize the activation of CXCR1. This
finding could have important implications in the regulation of
inflammation, as CXCR1 agonists could operate as selective anti-
Figure 2. R6H-CXCL8 is a full CXCR1 agonist and binds to HL60
cells expressing CXCR1. A. Dose-dependent calcium responses in
HL-60 cells expressing CXCR1. HL-60 cells expressing CXCR1 loaded
with Indo-1 were stimulated with different concentrations of wild-type
CXCL8 or R6H-CXCL8 mutant. The intracellular calcium response
stimulated by 100 nM CXCL8 is referred as 100%. The EC50s of R6H-
CXCL8 and CXCL8 were 54 nM and 4 nM, respectively. Values are
means of triplicate determinations, and the bars of each point represent
the standard errors B. HL-60 cells expressing CXCR1 or CXCR2 were
incubated with
125I-CXCL8 (0.16 nM) in the absence or presence of
increasing concentrations of unlabeled CXCL8 or R6H-CXCL8 mutant at
4uC for 5 h. The 100% specific binding corresponded to the binding of
125I-CXCL8 in the absence of unlabeled chemokine minus the binding of
125I-CXCL8 in the presence of 200 nM of unlabeled CXCL8. The IC50s for
R6H-CXCL8 and CXCL8 were 504 and 14 nM, respectively. Values are
means of triplicate determinations, and the bars of each point represent
the standard errors.
doi:10.1371/journal.pone.0027967.g002
Figure 3. R6H-CXCL8 and CC-CXCL8 mutants triggered inter-
nalization of CXCR1. HEK 293 cells were transiently transfected with
plasmids encoding CXCR1 or CXCR2 fused to GFP. Transfected cells
were treated with 100 nM of CXCL8, R6H-CXCL8 or CC-CXCL8 mutants
for 30 min at 37uC. Fluorescence was recorded by using a confocal
microscope.
doi:10.1371/journal.pone.0027967.g003
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which is responsible for the accumulation of neutrophils into
inflamed tissues due to injury or infection [4]. Engineering
selective CXCR1 antagonists will complement the studies with the
CXCR1 agonists in further defining the significance of CXCR1 in
pathophysiological conditions.
Importantly, these novel CXCR1 agonists are revealing for the
first time the key structural elements in chemokines for the
activation of CXCR1 and CXCR2, and compels to revise the
current two-state model involving the interaction of chemokines
with their cognate receptors. In this new model, the interactions of
CXCL8 with CXCR1 and CXCR2 are different. On the basis of
our data and previous studies [15,16,17,18] CXCL8 binds to
CXCR1 according to the classical two-site model (Fig. 7a), in
which the N-loop of CXCL8 interacts with a receptor site (Site 1)
defined by the N-terminus of CXCR1, a major determinant for
the selective binding to CXCL8 to CXCR1. Site2 in CXCR1
binds to Glu4 of CXCL8 to trigger receptor activation without a
major contribution from Arg6 or the CXC motif. On the other
hand, we propose a new model for the interaction of CXCL8 with
CXCR2, in which CXCR2 binds to the N-terminus of CXCL8
(Glu4, Arg6 and CXC motif) to trigger receptor activation,
without significant contributions of either the N-terminus of the
receptor or the N-loop of CXCL8 (Fig. 7b), as demonstrated by
the broad binding of CXCR2 to all ELR-CXC chemokines
containing non-conserved residues in their N-loops [19], and by
the studies showing that the CXCR2 chimera containing the non-
related N-terminus of the chemokine receptor CCR1 is still
activated by all ELR-chemokines [17]. Finally, DARC is a hybrid
of CXCR1/CXCR2, the conserved ELR-CXC in chemokines is
required for binding to DARC, but the N-terminus of DARC is
required for its binding to multiple chemokines (ELR-CXC and
CC chemokines), as the CXCR2 mutant containing the DARC N-
terminus exhibits the same binding profile as wild type DARC
[14].
Optimization of our CXCR1 agonists will help designing more
potent CXCR1 agonists and antagonists, which can be used as
inflammatory modulators for the treatment of life threatening
inflammatory disorders.
Materials and Methods
Expression and Purification of CXCL8 Mutants
cDNA encoding the human CXCL8 (1–66) were cloned into
the E.coli expression vector pET32-Xa-Lic, which is used as
template for engineering CXCL8 mutants by site directed
mutagenesis. The wild type CXCL8 and mutants were expressed
in E.coli BL21 (DE3) pLys and purified by chromatography
Figure 4. The R6H-CXCL8 mutant activated CXCR1 in neutro-
phils. Human neutrophils loaded with Indo-1 were treated with and
without 1 mM of the CXCR2 inhibitor SB225002 and stimulated with
100 nM of CXCL8 (A and D), the CXCR2 agonist CXCL1 (B and E) and the
R6H-CXCL8 mutant (C and F). The record is representative of at least five
independent experiments.
doi:10.1371/journal.pone.0027967.g004
Figure 5. The R6H-CXCL8 and CC-CXCL8 mutants differentially
desensitized the calcium responses mediated by CXCR2.
Human neutrophils loaded with Indo-1 were first stimulated with
100 nM of R6H-CXCL8 and then challenged with 100 nM R6H-CXCL8 (A)
or the 100 nM CXCR2 agonist CXCL1 (C). Similarly, neutrophils were first
stimulated with 100 nM of CC-CXCL8 and then challenged with 100 nM
CC-CXCL8 (B) or 100 nM CXCL1 (D). Conversely, neutrophils were first
treated with 100 nM CXCL1 and then challenged with 100 nM of R6H-
CXCL8 (E) or CC-CXCL8 (F).
doi:10.1371/journal.pone.0027967.g005
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column or reverse phase column as described [11]. Alternatively,
CXCL8 and mutants were also expressed in Insect S2 cells, which
secrete CXCL8 mutants into the culture media. .
Intracellular Ca
2+ Mobilization
Human neutrophils were incubated with 5 mM Indo-1AM in
Hank’s solution without Ca
2+ and Mg
2+ at a density of ,10
7 cells/
ml for 30 min at 37uC in the dark. HL60 cells expressing CXCR1
and CXCR2 were loaded as for neutrophils except that the cells
were loaded with Indo-1 in RPMI. Subsequently, neutrophils and
HL60 cells were washed with PBS and then resuspended in buffer
containing 25 mM Hepes (pH 7.4), 125 mM NaCl, 5 mM KCl,
1 mM CaCl2, 0.5 mM MgCl2, 1 mM NaH2PO4, 0.1% bovine
serum albumin, 0.1% glucose at a density of 10
7 cells/ml. We
employed 10
6 cells/ml to record intracellular calcium in
RF5301PC spectrofluorometer (Shimadzu), using an excitation
wavelength of 330 nm and an emission wavelength of 405 nm, as
described [20].
125I-CXCL8 and
125I-CXCL1 Binding
HL-60 cells (2610
7 cells/ml) expressing CXCR1 or CXCR2 or
ghost membranes (75 ug of protein/ml) from human red blood
cells were incubated at 4uC for 4–6 h in PBS supplemented with
0.1% (w/v) bovine serum albumin and 20 mM HEPES (pH 7.4),
125I-CXCL8 and
125I-CXCL1, in the absence and presence of
unlabeled CXCL8 or CXCL8 mutants. The binding reaction for
HL60 cells was terminated by centrifugation at 2006g for 5 min
over a 10% sucrose cushion. The binding reaction for ghost
membranes was terminated as for binding to HL60 cells, except
that the centrifugation was carried out at 13,0006g for 5 min. The
cell or membrane pellets were counted in a c-counter.
Internalization of CXCR1 and CXCR2. cDNA encoding
CXCR1 or CXCR2 were cloned in frame to EGFP in the
mammalian expression vector pEGFP-N1. HEK 293 cells
(150,000 cells) grown in glass cover slips coated with poly L-
lysine (0.01%) were transiently transfected with the plasmids (1 mg
DNA) encoding the chimeric receptors, by using Fugene-6. After
48 h the transfected cells were treated with CXCL8 or CXCL8
mutants for 30 min at 37C, then the cells were fixed with
methanol at 220C for 45 min and stained with DAPI. The
fluorescence was recorded by using a confocal microscope (Bio
Rad Radiance 2100).
Expression of CXCR1 and CXCR2. HL-60 expressing
CXCR1 and CXCR2 were engineered as described [11].The
NR1/CR2 mutant cDNA encoded the transplantation of the N-
terminus of CXCR1 into CXCR2 was constructed according to
[15]. COS-7 were transiently transfected with the following
constructs, CXCR1, CXCR2 and NR1/CR2 cloned into the
expression vector pSVL using Fugene 6. After 48 hours the cells
were harvested and bound to
125I-CXCL8 in the presence and
absence of unlabeled CXCL8 wild-type and mutants, as described
[15].
Rabbit skin inflammation. New Zealand rabbits (3–4 Kg)
were maintained in the Animal Facility of the Universidad
Peruana Cayetano Heredia (UPCH). Chemokine derivatives were
injected into the shaved dorsal skin of rabbits, as described [21].All
surgery was performed under sodium pentobarbital anesthesia,
and all efforts were made to minimize suffering. This study was
carried out in strict accordance with the recommendations in the
Guide for the Care and Use of Laboratory Animals of the National
Institutes of Health. The protocol was approved by the
Institutional Ethics Committee for Animal Use (CIAE) of the
Universidad Peruana Cayetano Heredia (Permit SIDISI 58343).
Supporting Information
Figure S1 The mutants R6X-CXCL8 triggered calcium
responses in HL-60 cells expressing CXCR1. HL-60 cells
Figure 6. R6H-CXCL8 and CC-CXCL-8 mutants bound to the
mutant CXCR2 containing the N-terminus of CXCR1. COS-7 cells
transfected with plasmids encoding CXCR1, CXCR2 or the NR1/CR2
(chimera in which N-terminus of CXCR2 was replaced by N-terminus of
CXCR1, as described [15] were incubated with
125I-CXCL8 (1 nM) in the
absence (total binding) or presence of 100 nM unlabeled CXCL8 or
1 mM R6H-CXCL8 or CC-CXCL8. Values are means of triplicate
determinations, and the bars of each point represent the standard
errors.
doi:10.1371/journal.pone.0027967.g006
Figure 7. Models for the interaction of CXCL8 with CXCR1 and
CXCR2. a. The N loop of CXCL8 (blue) binds to CXCR1 in site 1, which
includes the N-terminus of CXCR1 (blue), the major determinant for the
selective high affinity binding to CXCL8. Site 2 in CXCR1 binds Glu4
(sphere) of CXCL8 to trigger receptor activation. b. CXCR2 binds to the
N-terminus of CXCL8 (Glu4, Arg6 and CXC are represented as spheres)
to elicit receptor activation.
doi:10.1371/journal.pone.0027967.g007
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stimulated with 1 mM R6X-CXCL8 mutants. The percentages
of intracellular calcium responses are estimated from the calcium
signal elicited by permeabilization of the cells with the detergent
dodecylmaltoside (referred as 100%). The record is representative
of at least five independent experiments.
(TIF)
Figure S2 The mutant R6H-CXCL8 did not displace the
125I-CXCL1 or
125I-CXCL8 bound to HL-60 cells express-
ing CXCR2. HL-60 cells expressing CXCR2 were incubated
with
125I-CXCL1 (1 nM, A)o r
125I-CXCL8 (0.16 nM, B) in the
absence or presence of increasing concentrations of unlabeled
CXCL1 or CXCL8 or R6H-CXCL8 or CC-CXCL8 at 4uC for
5 h. The 100% specific binding corresponded to the binding of
125I-CXCL1 in the absence of unlabeled chemokine minus the
binding of
125I-CXCL1 in the presence of 200 nM of unlabeled
CXCL1 (A). Similarly, the 100% specific binding corresponded to
the binding of
125I-CXCL8 in the absence of unlabeled chemokine
minus the binding of
125I-CXCL8 in the presence of 200 nM of
unlabeled CXCL8 (B). Values are means of triplicate determina-
tions, and the bars of each point represent the standard errors.
(TIF)
Figure S3 Dose-dependent calcium responses in HL-60
cells expressing CXCR1. HL-60 cells expressing CXCR1
loaded with Indo-1 were stimulated with different concentrations
of wild-type CXCL8 or CC-CXCL8. The intracellular calcium
response stimulated by 100 nM CXCL8 is referred as 100%. The
EC50s for CC-CXCL8 and CXCL8 were 316 nM and 4 nM,
respectively. Values are means of triplicate determinations, and
the bars of each point represent the standard errors.
(TIF)
Figure S4 R6H-CXCL8 and CC-CXCL8 mutants in-
duced skin inflammation in rabbits. Prostaglandin E2
(PGE2, 30 nmol per 100 ul) was injected alone (control) or co-
injected with 100 nmol of CXCL8, R6H-CXCL8 or CC-CXCL8
into the shaved dorsal skin of rabbits. After 3 h the animals were
sacrificed and skin sections were stained with hematoxylin and
eosin to identify neutrophil infiltration.
(TIF)
Figure S5 R6H-CXCL8 and CC-CXCL8 mutants did not
bind Duffy antigen (DARC). Ghost membranes were
incubated with
125I-CXCL1 (1 nM) in the absence or presence
of increasing concentrations of unlabeled CXCL1, CXCL8, R6H-
CXCL8 or CC-CXCL8 mutant at 4uC for 5 h. The 100% specific
binding corresponded to the binding of
125I-CXCL1 in the
absence of unlabeled chemokine minus the binding of
125I-
CXCL1 in the presence of 200 nM of unlabeled CXCL1. The
IC50s of CXCL1 and CXCL8 were 13.4 and 45 nM, respectively.
Values are means of triplicate determinations, and the bars of each
point represent the standard errors.
(TIF)
Figure S6 The R6X-CXCL8 and CC-CXCL8 mutants
triggered calcium responses in neutrophils. Human
neutrophils loaded with Indo-1 and treated or untreated with
1 mM SB225002 were stimulated with 1 mM R6X-CXCL8
mutants or 200 nM of CC-CXCL8. The percentages of
intracellular calcium responses are estimated from the calcium
signal elicited by permeabilization of the cells with the detergent
dodecylmaltoside (referred as 100%). The record is representative
of at least five independent experiments.
(TIF)
Figure S7 CC-CXCL8 did not block the calcium re-
sponses mediated by CXCR2. HL-60 cells expressing
CXCR2 loaded with Indo-1 were first stimulated with 1 mM
CC-CXCL8 mutant and then challenged with 100 nM CXCL1
and followed by a second dose of 100 nM CXCL1.
(TIF)
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